As of December 31, 2024, a total of 109 patients with R/R MM had received Fucaso, 12.8% had EMD and 11% had received prior BCMA CAR-T therapy. Following lymphodepletion with cyclophosphamide and ...
The FDA's endorsement of MRD negativity as a surrogate endpoint may influence future regulatory decisions and clinical trial designs in multiple myeloma. High-risk myeloma is defined by specific ...
SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 18, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and ...
The MarketWatch News Department was not involved in the creation of this content. SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 18, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results